BRIEF-Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS

5

Oct 12 (Reuters) – Bristol-Myers Squibb Company: * BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE INTERIM ANALYSIS OF PHASE 3 ACTION-1 FOR RYZ101, RAYZEBIO’S RADIOPHARMACEUTICAL

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)